Beta

Biomx inc.PHGE.US Overview

US StockHealthcare
(No presentation for PHGE)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

PHGE AI Insights

PHGE Overall Performance

PHGE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PHGE Recent Performance

-15.69%

Biomx inc.

-1.10%

Avg of Sector

-0.49%

S&P500

PHGE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check PHGE's Trend

PHGE Key Information

PHGE Valuation Metrics

PHGE Profile

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Price of PHGE

PHGE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PHGE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-32.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
19.39
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-32.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
19.39
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PHGE's latest earnings report released?

    The most recent financial report for Biomx inc. (PHGE) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PHGE's short-term business performance and financial health. For the latest updates on PHGE's earnings releases, visit this page regularly.

  • How much cash does PHGE have?

    At the end of the period, Biomx inc. (PHGE) held Total Cash and Cash Equivalents of 4.96M, accounting for 0.86 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PHGE's EPS continuing to grow?

    According to the past four quarterly reports, Biomx inc. (PHGE)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -37.39. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PHGE?

    Biomx inc. (PHGE)'s Free Cash Flow (FCF) for the period is -4.39M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 30.29% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PHGE?

    The latest valuation data shows Biomx inc. (PHGE) has a Price-To-Earnings (PE) ratio of -0.23 and a Price/Earnings-To-Growth (PEG) ratio of -0.11. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.